Similar results were found for the cumulative incidence of clinically significant prostate cancer diagnosis and prostate cancer treatment, with a strong dependence on baseline PSA for each (clinically significant prostate cancer: 10-year cumulative incidence, 7.41% for PSA 3.00-3.99 ng/mL vs 0.32% for PSA 0.20-0.99 ng/mL; prostate cancer treatment: 10-year cumulative incidence, 8.25% for PSA 3.00-3.99 ng/mL vs 0.37% for PSA 0.20-0.99 ng/mL) (eFigures 4 and 5 in Supplement 1). This evidence concerns the gene KLK3 and Familial prostate cancer.